Safety evaluation of recombinant human interleukin-4. II. Clinical studies

Clinical Immunology and Immunopathology

Volumn 83, Issue 1, 1997, Pages 12-14

  Leach, Michael W ^a   Rybak, Mary Ellen ^a   Rosenblum, I Y ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 4;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE; FEVER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; TOXICITY;

EID: 0031127016     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4304     Document Type: Conference Paper

References (23)

1. 1. Banchereau, J., Brière, F., Galizzi, J. P., Miossec, P., and Rousset, F., Human interleukin 4. J. Lipid Mediators Cell Signalling 1994.
2. 2. Banchereau, J., and Rybak, M. E., Interleukin-4. In "The Cytokine Handbook" (A. W. Thomson, Ed.), pp. 99-126, Academic Press, London, 1994.
3. 3. Paul, W. E., Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77, 1859-1870, 1991.
4. 4. Street, N. E., and Mosmann, T. R., IL4 and IL5: The role of two multifunctional cytokines and their place in the network of cytokine interactions. Biotherapy 2, 347-362, 1990.
5. 5. Tepper, R. I., Pattengale, P. K., and Leder, P., Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57, 503-512, 1989.
6. 6. Tepper, R. I., Coffman, R. L., and Leder, P., An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257, 548-551, 1992.
7. 7. Hillman, G. G., Younes, E., Visscher, D., Ali, E., Lam, J. S., Montecillo, E., Pontes, J. E., Haas, G. P., and Puri, R. K., Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model. Cell. Immunol. 160, 257-263, 1995.
8. 8. Tepper, R. I., The eosinophil-mediated antitumor activity of interleukin-4. J. Allergy Clin. Immunol. 94, 1225-1231, 1994.
9. 9. Younes, E., Haas, G. P., Visscher, D., Pontes, J. E., Puri, R. K., and Hillman, G. G., Intralesional treatment of established murine primary renal tumor with interleukin-4: Localized effect on primary tumor with no impact on metastases. J. Virol. 153, 490-493, 1995.
10. 10. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., and Pardoll, D. M., Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716, 1991.
11. 11. Addison, C. L., Gauldie, J., Muller, W. J., and Graham, F. L., An adenoviral vector expressing interleukin-4 modulates tumorigenicity and induces regression in a murine breast cancer model. Int. J. Oncol. 7, 1253-1260, 1995.
12. 12. Lahm, H., Schnyder, B., Wyniger, J., Borbenyi, Z., Yilmaz, A., Car, B. D., Fischer, J. R., Givel, J.-C., and Ryffel, B., Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors. Int. J. Cancer 59, 440-447, 1994.
13. 13. Rybak, M. E., and Catino, J. J., An overview of the clinical use of recombinant human interleukin-4. In "Cytokines in Hematopoiesis, Oncology, and Immunology III" (M. Freund, H. Link, R. Schmidt, and K. Welte, Eds.), pp. 39-45, Springer-Verlag, Berlin, 1994.
14. 14. Sharpe, N. A., Leach, M. W., Radwanski, E., Swanson, S., DeGroat, L., Schmahai, T. J., and Rosenblum, I. Y., Local and systemic effects following a single intra-articular administration of recombinant human interleukin-4 in female monkeys. Fundam. Appl. Toxicol. (Suppl.) 30, 109-110, 1996.
15. 15. Snyder, E., Leach, M., Sinha, D., Halliwell, W., McCullough, B., and Rosenblum, I., Effects of subcutaneous rhuIL-4 in cynomolgus monkeys. Fundam. Appl. Toxicol. (Suppl.) 30, 107-108, 1996.
16. 16. Leach, M., Snyder, E., Sinha, D., Halliwell, W., McCullough, B., and Rosenblum, I., Pathologic findings in cynomolgus monkeys administered IL-4. Fundam. Appl. Toxicol. (Suppl.) 30, 107, 1996.
17. 17. Leach, M. W., Snyder, E. A., Sinha, D. P., and Rosenblum, I. Y., Safety evaluation of recombinant human interleukin-4. I. Preclinical studies. Clin. Immunol. Immunopathol. 83, 8-11, 1997.
18. 18. Gilleece, M. H., Scarffe, J. H., Ghosh, A., Heyworth, C. M., Bonnem, E., Testa, N., Stern, P., and Dexter, T. M., A recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections - A phase I dose toxicity trial. Br. J. Cancer 66, 204-210, 1992.
19. 19. Vokes, E., Hochster, H., Lotze, M., Figlin, R., and Rybak, M. E., Recombinant human interleukin 4 (IL-4) SCH 39400 in non-small cell lung cancer (NSCLC): Results of a phase II investigation. Proc. Am. Soc. Clin. Oncol. 13, 334, 1994.
20. 20. Stadler, W. M., Rybak, M. E., and Vogelzang, N. J., A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer 76, 1629-1633, 1995.
21. 21. Trehu, E. G., Isner, J. M., Mier, J. W., Karp, D. D., and Atkins, M. B., Possible myocardial toxicity associated with interleukin-4 therapy. J. Immunother. 14, 348-351, 1993.
22. 22. Atkins, M. B., Vachino, G., Tilg, H. J., Karp, D. D., Robert, N. J., Kappler, K., and Mier, J. W., Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J. Clin. Oncol. 10, 1802-1809, 1992.
23. 23. Margolin, K, Aronson, F. R., Sznol, M., Atkins, M. B., Gucalp, R., Fisher, R. I., Sunderland, M., Doroshow, J. H., Ernest, M. L., Mier, J. W., Dutcher, J. P., Gaynor, E. R., and Weiss, G. R., Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J. Immunother. 15, 147-153, 1994.